Page last updated: 2024-09-04

ruboxistaurin and Diabetic Nephropathies

ruboxistaurin has been researched along with Diabetic Nephropathies in 28 studies

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's25 (89.29)29.6817
2010's3 (10.71)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alicic, RZ; Tuttle, KR1
Cazenave, M; Gauthier, M; Gueutin, V; Izzedine, H1
Ahmed, RM; Al-Amin, MA; Al-Onazi, AS; Al-Rasheed, NM; Attia, HA; Poizat, C1
Cherney, DZ; Diamandis, EP; Konvalinka, A; Lai, V; Lorraine, J; Miller, JA; Reich, H; Scholey, JW; Soosaipillai, A; Zinman, B1
Gao, B; Gilbert, RE; Ingram, AJ; Kelly, DJ; Krepinsky, JC; Peng, F; Wu, D; Zhang, B1
Haller, H; Meier, M; Menne, J1
Bakris, GL; Burney, BO; Kalaitzidis, RG1
Inoguchi, T; Umeda, F1
Gilbert, RE; Gow, RM; Hepper, C; Jaworski, K; Kelly, DJ; Kemp, BE; Wilkinson-Berka, JL; Zhang, Y1
Anderson, PW; Tuttle, KR1
Araki, S; Haneda, M; Isono, M; Kashiwagi, A; Kitada, M; Koya, D; Sugimoto, T1
Tuttle, KR; Williams, ME1
Chanty, A; Gilbert, RE; Gow, RM; Kelly, DJ; Zhang, Y1
Tuttle, KR1
Bearelly, S; Cooney, MJ; Dar, M; Goebel, JA; Joy, SV; Scates, AC; Taulien, CA1
Bastyr, EJ; Bril, V; Kempler, P; Litchy, WJ; Price, KL; Tesfaye, S; Vinik, AI1
Anderson, PW; Bakris, GL; Hu, K; McGill, JB; Toto, RD; Tuttle, KR1
Joy, SV; Taulien, CA1
Andrassy, M; Fujita, T; Harja, E; Schmidt, AM; Yan, SF1
Williams, ME1
Anderson, PW; Bakris, GL; Gilbert, RE; Haney, DJ; Kelly, DJ; Kim, SA; McGill, JB; Toto, RD; Tuttle, KR1
Anderson, PW; McGill, JB; Tuttle, KR1
Anderson, PW; Haney, DJ; Lin, TE; McGill, JB; Tuttle, KR1
Fantus, IG; Frecker, H; Goldberg, HJ; Munk, S; Wang, H; Whiteside, CI; Xia, L1
Shah, SV; Swaminathan, S1
Haneda, M; Isshiki, K; Kashiwagi, A; Kikkawa, R; King, GL; Koya, D; Maeda, S; Nakagawa, H; Sato, H; Sugimoto, T; Ways, DK; Yasuda, H1

Reviews

14 review(s) available for ruboxistaurin and Diabetic Nephropathies

ArticleYear
Novel therapies for diabetic kidney disease.
    Advances in chronic kidney disease, 2014, Volume: 21, Issue:2

    Topics: Acetylcysteine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antioxidants; Bosentan; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelins; Enzyme Inhibitors; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Indoles; Janus Kinases; Maleimides; Polyamines; Protein Kinase C; Pyridones; Pyridoxamine; Sevelamer; Sulfonamides

2014
[Diabetic nephropathy: emerging treatments].
    Nephrologie & therapeutique, 2014, Volume: 10, Issue:4

    Topics: Adrenocorticotropic Hormone; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antifibrinolytic Agents; Antineoplastic Agents, Hormonal; Antioxidants; Bone Density Conservation Agents; Diabetic Nephropathies; Doxycycline; Enzyme Inhibitors; Ergocalciferols; Hormones; Humans; Indoles; Maleimides; Octreotide; Pentoxifylline; Pyridones; Pyridoxamine; Silymarin; Vitamin B Complex

2014
Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice.
    Diabetologia, 2009, Volume: 52, Issue:5

    Topics: Animals; Diabetic Nephropathies; Diabetic Neuropathies; Enzyme Activation; Enzyme Inhibitors; Humans; Hyperglycemia; Indoles; Isoenzymes; Kidney; Maleimides; Mice; Mice, Knockout; Mice, Mutant Strains; Mice, Transgenic; Models, Animal; Protein Kinase C; Protein Kinase C beta; Risk Factors

2009
Novel therapies of diabetic nephropathy.
    Current opinion in nephrology and hypertension, 2009, Volume: 18, Issue:2

    Topics: Amides; Animals; Diabetic Nephropathies; Fumarates; Humans; Indoles; Maleimides; Pyridoxamine; Superoxides

2009
[Role of PKC in the pathogenesis of diabetic vascular complications].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 10

    Topics: Animals; Clinical Trials as Topic; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Humans; Indoles; Isoenzymes; Maleimides; Protein Kinase C; Protein Kinase C beta; Risk Factors

2002
A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003, Volume: 42, Issue:3

    Topics: Animals; Animals, Genetically Modified; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathies; Drug Evaluation, Preclinical; Endothelium, Vascular; Enzyme Inhibitors; Female; Humans; Indoles; Kidney Failure, Chronic; Male; Maleimides; Mice; Mice, Mutant Strains; Protein Kinase C; Protein Kinase C beta; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Receptors, Leptin; Renin

2003
The next generation of diabetic nephropathy therapies: an update.
    Advances in chronic kidney disease, 2005, Volume: 12, Issue:2

    Topics: Animals; Diabetic Nephropathies; Disease Progression; Enzyme Inhibitors; Glycation End Products, Advanced; Glycosaminoglycans; Humans; Indoles; Maleimides; Models, Animal; Protein Kinase C; Pyridoxamine; Renal Agents; Thiazoles

2005
Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:10

    Topics: Animals; Clinical Trials as Topic; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Enzyme Inhibitors; Humans; Indoles; Maleimides; MEDLINE; Protein Kinase C; Protein Kinase C beta; Treatment Outcome

2005
Ruboxistaurin.
    Drugs of today (Barcelona, Spain : 1998), 2006, Volume: 42, Issue:9

    Topics: Animals; Clinical Trials as Topic; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Humans; Indoles; Maleimides; Protein Kinase C

2006
Protein kinase C beta/early growth response-1 pathway: a key player in ischemia, atherosclerosis, and restenosis.
    Journal of the American College of Cardiology, 2006, Nov-07, Volume: 48, Issue:9 Suppl 1

    Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetic Angiopathies; Diabetic Nephropathies; Disease Models, Animal; Early Growth Response Protein 1; Endothelium, Vascular; Humans; Indoles; Maleimides; Mice; Mitogen-Activated Protein Kinase Kinases; Myocardial Ischemia; Oxidative Stress; Phosphorylation; Protein Kinase C; Protein Kinase C beta; Signal Transduction; Tunica Intima; Up-Regulation

2006
New potential agents in treating diabetic kidney disease: the fourth act.
    Drugs, 2006, Volume: 66, Issue:18

    Topics: Animals; Diabetic Nephropathies; Drugs, Investigational; Glycation End Products, Advanced; Glycosaminoglycans; Humans; Indoles; Maleimides; Protein Kinase C; Protein Kinase Inhibitors; Pyridoxamine; Renal Agents; Treatment Outcome

2006
Ruboxistaurin: LY 333531.
    Drugs in R&D, 2007, Volume: 8, Issue:3

    Topics: Animals; Clinical Trials as Topic; Diabetes Complications; Diabetic Nephropathies; Diabetic Retinopathy; Drugs, Investigational; Humans; Indoles; Maleimides; Protein Kinase C; Rats

2007
Protein kinase C beta inhibition: the promise for treatment of diabetic nephropathy.
    Current opinion in nephrology and hypertension, 2007, Volume: 16, Issue:5

    Topics: Animals; Clinical Trials as Topic; Diabetic Nephropathies; Glomerular Filtration Rate; Humans; Indoles; Maleimides; Models, Chemical; Protein Kinase C; Protein Kinase C beta; Treatment Outcome

2007
Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease.
    Current opinion in nephrology and hypertension, 2008, Volume: 17, Issue:2

    Topics: Biomarkers; Chronic Disease; Diabetic Nephropathies; Disease Progression; Drugs, Investigational; Glycation End Products, Advanced; Humans; Indoles; Iron; Kidney; Kidney Diseases; Maleimides; Oxidative Stress; Protein Kinase C; Protein Kinase Inhibitors; Pyridoxamine; Reactive Oxygen Species; Treatment Outcome; Vitamin B Complex

2008

Trials

4 trial(s) available for ruboxistaurin and Diabetic Nephropathies

ArticleYear
Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
    Clinical therapeutics, 2005, Volume: 27, Issue:8

    Topics: Adult; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Indoles; Male; Maleimides; Middle Aged; Protein Kinase C; Protein Kinase C beta

2005
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
    Diabetes care, 2005, Volume: 28, Issue:11

    Topics: Aged; Albuminuria; Black or African American; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Enzyme Inhibitors; Female; Glomerular Filtration Rate; Humans; Indoles; Male; Maleimides; Middle Aged; Pilot Projects; Time Factors; United States; White People

2005
Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.
    Diabetes care, 2007, Volume: 30, Issue:4

    Topics: Adult; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Enzyme Inhibitors; Humans; Indoles; Maleimides; Middle Aged; Placebos; Protein Kinase C; Protein Kinase C beta; Transforming Growth Factor beta

2007
Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease.
    Clinical journal of the American Society of Nephrology : CJASN, 2007, Volume: 2, Issue:4

    Topics: Diabetic Nephropathies; Diabetic Retinopathy; Double-Blind Method; Female; Humans; Indoles; Kidney; Male; Maleimides; Middle Aged; Protein Kinase C; Time Factors

2007

Other Studies

10 other study(ies) available for ruboxistaurin and Diabetic Nephropathies

ArticleYear
Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways.
    The Journal of pharmacy and pharmacology, 2016, Volume: 68, Issue:2

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; GRB2 Adaptor Protein; Indoles; Kidney Function Tests; Male; Maleimides; Protein Kinase C beta; Rats, Wistar; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta1

2016
Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Albuminuria; Blood Pressure; Chemokine CCL2; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Enzyme Inhibitors; Epidermal Growth Factor; Glomerular Filtration Rate; Hemodynamics; Humans; Indoles; Kidney; Maleimides; Protein Kinase C; Protein Kinase C beta

2009
PKC-beta1 mediates glucose-induced Akt activation and TGF-beta1 upregulation in mesangial cells.
    Journal of the American Society of Nephrology : JASN, 2009, Volume: 20, Issue:3

    Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Activation; ErbB Receptors; Female; Glucose; Indoles; Kidney; Maleimides; Mesangial Cells; Models, Biological; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats; Recombinant Proteins; Signal Transduction; Transcription Factor AP-1; Transcriptional Activation; Transforming Growth Factor beta1; Up-Regulation

2009
Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension.
    Diabetes, 2003, Volume: 52, Issue:2

    Topics: Albuminuria; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathies; Disease Progression; Enzyme Inhibitors; Female; Hypertension; Immunohistochemistry; Indoles; Kidney; Kidney Glomerulus; Maleimides; Organ Size; Protein Kinase C; Protein Kinase C beta; Rats; Rats, Mutant Strains; Reference Values

2003
Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy.
    Diabetes, 2003, Volume: 52, Issue:10

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Biological Transport; Deoxyguanosine; Diabetic Nephropathies; Enzyme Activation; Enzyme Inhibitors; Indoles; Isoenzymes; Kidney Glomerulus; Male; Maleimides; Membranes; NADPH Oxidases; Oxidative Stress; Phosphoproteins; Protein Kinase C; Protein Kinase C beta; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; RNA, Messenger; Staining and Labeling

2003
Molecule of the month. Ruboxistaurin mesilate hydrate.
    Drug news & perspectives, 2003, Volume: 16, Issue:10

    Topics: Clinical Trials, Phase II as Topic; Diabetes Complications; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Humans; Indoles; Maleimides

2003
Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy.
    Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:6

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Inhibitors; Female; Indoles; Kidney; Macrophage Activation; Maleimides; Nephritis, Interstitial; Osteopontin; Protein Kinase C; Protein Kinase C beta; Rats; Sialoglycoproteins; Transforming Growth Factor beta; Transforming Growth Factor beta1

2005
Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease.
    Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:6

    Topics: Animals; Diabetic Nephropathies; Enzyme Inhibitors; Humans; Indoles; Intercellular Adhesion Molecule-1; Kidney; Maleimides; Mice; Models, Animal; Protein Kinase C; Protein Kinase C beta; Rats

2005
Reactive oxygen species, PKC-beta1, and PKC-zeta mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells.
    American journal of physiology. Endocrinology and metabolism, 2007, Volume: 293, Issue:5

    Topics: Animals; Cyclic N-Oxides; Diabetic Nephropathies; Fluorescent Antibody Technique; Glucose; Indoles; Maleimides; Mesangial Cells; Molecular Chaperones; NADPH Oxidases; Oligodeoxyribonucleotides, Antisense; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Rats; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spin Labels; Vascular Endothelial Growth Factor A

2007
Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2000, Volume: 14, Issue:3

    Topics: Albuminuria; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enzyme Inhibitors; Gene Expression Regulation; Glomerular Mesangium; Indoles; Isoenzymes; Kidney Glomerulus; Male; Maleimides; Mice; Mice, Mutant Strains; Protein Kinase C; Protein Kinase C beta; Rats; Transforming Growth Factor beta

2000